Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer
NCT ID: NCT00140075
Last Updated: 2011-05-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
606 participants
INTERVENTIONAL
2000-11-30
2006-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility
NCT00617370
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
NCT00129935
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
NCT00055679
Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)
NCT00590785
Combination Chemotherapy in Treating Women With Breast Cancer
NCT00003519
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
B
ET (8 cycles)
T = docetaxel or paclitaxel
Epirubicin with a Taxane
Epirubicin = 75 mg/m2 per cycle
Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
A
EC (4 cycles) followed by T (4 cycles) for a total of 8 cycles
T = docetaxel or paclitaxel
Epirubicin with Cyclophosphamide, followed by a Taxane
Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2
Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Epirubicin with Cyclophosphamide, followed by a Taxane
Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2
Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Epirubicin with a Taxane
Epirubicin = 75 mg/m2 per cycle
Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Suitable candidate for anthracycline-containing adjuvant chemotherapy
Exclusion Criteria
* Received prior therapy for breast cancer
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Pfizer Inc
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Bakersfield, California, United States
Pfizer Investigational Site
Berkeley, California, United States
Pfizer Investigational Site
Fountain Valley, California, United States
Pfizer Investigational Site
Fountian Valley, California, United States
Pfizer Investigational Site
Gilroy, California, United States
Pfizer Investigational Site
Poway, California, United States
Pfizer Investigational Site
Soquel, California, United States
Pfizer Investigational Site
Colorado Springs, Colorado, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Jacksonville, Florida, United States
Pfizer Investigational Site
Kissimmee, Florida, United States
Pfizer Investigational Site
Lake Worth, Florida, United States
Pfizer Investigational Site
Lecanto, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami Shores, Florida, United States
Pfizer Investigational Site
Port Saint Lucie, Florida, United States
Pfizer Investigational Site
Tampa, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Macon, Georgia, United States
Pfizer Investigational Site
Belleville, Illinois, United States
Pfizer Investigational Site
Skokie, Illinois, United States
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Harper Woods, Michigan, United States
Pfizer Investigational Site
Hattiesburg, Mississippi, United States
Pfizer Investigational Site
Jackson, Mississippi, United States
Pfizer Investigational Site
Mount Holly, New Jersey, United States
Pfizer Investigational Site
Willingboro, New Jersey, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Great Neck, New York, United States
Pfizer Investigational Site
Staten Island, New York, United States
Pfizer Investigational Site
Burlington, North Carolina, United States
Pfizer Investigational Site
Greenville, North Carolina, United States
Pfizer Investigational Site
Raleigh, North Carolina, United States
Pfizer Investigational Site
Lawton, Oklahoma, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Lemoyne, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Columbia, South Carolina, United States
Pfizer Investigational Site
Germantown, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Corpus Christi, Texas, United States
Pfizer Investigational Site
Tyler, Texas, United States
Pfizer Investigational Site
Arlington, Virginia, United States
Pfizer Investigational Site
Portsmouth, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
378-ONC-0030-184
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.